SCHEMBL6862833

SCHEMBL6862833

CCOc1cc(CO)cc2c1ccn2CC

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.38
KDM4E B2RXH2 2/20 0.35
RXFP1 Q9HBX9 1/20 0.35
LMNA P02545 2/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
GAA P10253 1/20 0.33
S1PR1 P21453 2/20 0.33
S1PR3 Q99500 1/20 0.33
SLC2A1 P11166 1/20 0.33
CREBBP Q92793 1/20 0.32
ALDH1A1 P00352 3/20 0.32
TUBB4A P04350 1/20 0.32
TUBB P07437 1/20 0.32
TUBA3C P0DPH7 1/20 0.32
TUBA1B P68363 1/20 0.32
TUBA4A P68366 1/20 0.32
TUBB4B P68371 1/20 0.32
TUBB3 Q13509 1/20 0.32
TUBB2A Q13885 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6867111 0.80 ALOX5AP (0.32)
SCHEMBL19579750 0.77 TSHR (0.48) HTTKDM4ELMNAMEN1KMT2A
SCHEMBL6872804 0.75 ALDH1A1 (0.47) KDM4ELMNAALDH1A1MAPT
SCHEMBL6870182 0.75 POLB (0.43) KDM4ERXFP1LMNAMEN1KMT2A
SCHEMBL6869280 0.73 DHFR (0.61) HTTMEN1KMT2AALDH1A1TSHR
SCHEMBL18045050 0.73 HTR6 (0.43) KDM4ELMNAMEN1KMT2AS1PR1
SCHEMBL3639906 0.68 HTT (0.41) HTTKDM4ELMNAMEN1KMT2A
SCHEMBL13144363 0.68 TSHR (0.53) HTTLMNAMEN1KMT2AGAA
SCHEMBL28492538 0.68 HTT (0.41) HTTKDM4ELMNAMEN1KMT2A
SCHEMBL1121450 0.67 DHFR (0.52) HTTLMNAGAAS1PR1S1PR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1280796-B1 PYRIMIDINYL METHYL INDOLE DERIVATIVES WITH ANTIBACTERIAL ACTIVITY BASILEA PHARMACEUTICA AG (CH) 2004-03-24 EP disclosed
US-6703397-B2 REACTING A NITRILE GROUP CONTAINING INDOLE DERIVEATIVE WITH GUANIDINE OR SALT; USEFUL AS PROHYLAXIS OR THERAPEUTICAL TREATMENT OF INFECTIOUS DISEASES BASILEA PHARMACEUTICA AG (CH) 2004-03-09 US disclosed
US-20030119857-A1 Pyrimidinyl methyl indole derivatives with antibacterial activity BASILEA PHARMACEUTICA AG (CH) 2003-06-26 US disclosed
EP-1280796-A1 PYRIMIDINYL METHYL INDOLE DERIVATIVES WITH ANTIBACTERIAL ACTIVITY Basilea Pharmaceutica AG (CH) 2003-02-05 EP disclosed
WO-2001083474-A1 PYRIMIDINYL METHYL INDOLE DERIVATIVES WITH ANTIBACTERIAL ACTIVITY BASILEA PHARMACEUTICA AG (CH) 2001-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030119857-A1 Pyrimidinyl methyl indole derivatives with antibacterial activity IDO1, IDO2, AANAT HTT 2407/4885KDM4E 2066/4885RXFP1 3474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.